Physician profile
Nardo Zaias
NPI 1952343923
$4,815.61
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $761 · 2021: $962 · 2022: $1,017 · 2023: $1,144 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.37 | 2019-2024 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $516.93 | 2019-2023 | |
| Journey Medical Corporation | $352.93 | 2019-2024 | |
| Lilly USA, LLC | $311.92 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $257.58 | 2020-2023 | Tremfya |
| Genzyme Corporation | $229.95 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $184.14 | 2021-2023 | Dupixent |
| Amgen INC. | $145.23 | 2019-2022 | |
| Pfizer INC. | $142.57 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.60 | 2023 | Spevigo |
| Leo Pharma INC. | $128.33 | 2019-2021 | |
| Biofrontera INC. | $113.88 | 2020-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $113.05 | 2019-2021 | |
| Incyte Corporation | $108.24 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $83.37 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $66.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.64 | 2023 | Sotyktu |
| Almirall LLC | $39.80 | 2022 | |
| Galderma Laboratories, L.P. | $24.00 | 2023 | |
| Acera Surgical, INC. | $20.07 | 2022 | |
| Genentech, INC. | $18.77 | 2023 | Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.12 | 2019 | |
| Organogenesis INC. | $16.96 | 2021 | |
| Celgene Corporation | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nardo Zaias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.